Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 16, 2026 to Discuss Your Rights – SKYE

Core Viewpoint - The Gross Law Firm is notifying shareholders of Skye Bioscience, Inc. regarding a class action lawsuit due to alleged misleading statements about the company's lead product candidate, nimacimab, which was claimed to be less effective than represented [1][3]. Group 1: Class Action Details - The class period for the lawsuit is from November 4, 2024, to October 3, 2025 [3]. - Allegations include that the defendants made materially false and misleading statements about nimacimab's effectiveness and its clinical, regulatory, and commercial prospects [3]. - The deadline for shareholders to register for the class action is January 16, 2026, and there is no cost to participate [4]. Group 2: Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to deceit and misleading practices by companies [5]. - The firm emphasizes the importance of responsible business practices and good corporate citizenship [5].